Allworth Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Allworth Financial’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.68K	Sell	239 -13	-5%	-$581	﹤0.01%	3610
2025 Q4	$11.7K	Buy	252 +32	+15%	+$1.43K	﹤0.01%	3155
2025 Q3	$9.16K	Buy	220 +85	+63%	+$2.72K	﹤0.01%	3198
2025 Q2	$3.88K	Buy	135 +130	+2,600%	+$4.01K	﹤0.01%	3401
2025 Q1	$167	Sell	5 -4	-44%	-$149	﹤0.01%	3903
2024 Q4	$348	Sell	9 -15	-63%	-$839	﹤0.01%	3684
2024 Q3	$1.23K	Sell	24 -6	-20%	-$309	﹤0.01%	3150
2024 Q2	$1.58K	Buy	30 +10	+50%	+$462	﹤0.01%	3021
2024 Q1	$937	Hold	20	–	–	﹤0.01%	3102
2023 Q4	$712	Sell	20 -28	-58%	-$859	﹤0.01%	3053
2023 Q3	$1.43K	Buy	+48	New	+$989	﹤0.01%	2696
2023 Q2	–	Sell	-100	Closed	-$1.61K	–	3280
2023 Q1	$1.61K	Buy	+100	New	+$1.85K	﹤0.01%	2502
2022 Q4	–	Sell	-10	Closed	–	–	3046
2022 Q3	$0	Buy	+10	New	+$204	﹤0.01%	2731

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Allworth Financial's CRNX Position: Q1 2026 in Review

Allworth Financial reduced its Crinetics Pharmaceuticals (CRNX) stake by 5.2% in Q1 2026, selling an estimated $581 and leaving 239 shares worth $8.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3610.

Allworth Financial first reported a position in CRNX in Q3 2022 and has held it in 13 quarters since. The position peaked at $11.7K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Allworth Financial held 239 shares of Crinetics Pharmaceuticals worth $8.68K as of Q1 2026.
Allworth Financial sold 13 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $581.
Crinetics Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #3610 holding.
Allworth Financial first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
Allworth Financial's Crinetics Pharmaceuticals position peaked at $11.7K in Q4 2025.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.